Iolyx Therapeutics

Iolyx Therapeutics is a clinical-stage immuno-ophthalmology company dedicated to transforming the standard of care at the intersection of autoimmunity and inflammatory eye disease. The company is developing immunology-driven therapeutics targeting both anterior and posterior ocular inflammation. Its lead program, ILYX-002, demonstrated rapid improvement in immune-mediated dry eye disease in a Phase 2 trial, and Iolyx secured a global development and commercialization partnership with Laboratoires Théa valued at up to $280 million. The company is advancing toward a Phase 3 program and is headquartered in Burlingame, California, bringing a differentiated immunological approach to conditions that have historically been underserved by existing ophthalmic therapies.